Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1972 5
1973 10
1974 17
1975 11
1976 15
1977 11
1978 9
1979 5
1980 9
1981 3
1982 5
1983 5
1984 2
1985 5
1986 1
1987 2
1989 1
1990 1
1992 2
1996 1
1997 1
1999 5
2000 8
2001 6
2002 9
2003 3
2005 1
2006 1
2012 1
2018 1
2019 1
2021 5
2022 5
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Results by year

Filters applied: . Clear all
Page 1
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, Kumar U, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy JS, Jahreis A, Genovese MC, Mozaffarian N, Landewé RBM, Bae SC, Keystone EC, Nash P. Combe B, et al. Among authors: matzkies f. Ann Rheum Dis. 2021 Jul;80(7):848-858. doi: 10.1136/annrheumdis-2020-219214. Epub 2021 Jan 27. Ann Rheum Dis. 2021. PMID: 33504485 Free PMC article. Clinical Trial.
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T. Genovese MC, et al. Among authors: matzkies f. JAMA. 2019 Jul 23;322(4):315-325. doi: 10.1001/jama.2019.9055. JAMA. 2019. PMID: 31334793 Free PMC article. Clinical Trial.
Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.
Price E, Bombardieri M, Kivitz A, Matzkies F, Gurtovaya O, Pechonkina A, Jiang W, Downie B, Mathur A, Mozaffarian A, Mozaffarian N, Gottenberg JE. Price E, et al. Among authors: matzkies f. Rheumatology (Oxford). 2022 Nov 28;61(12):4797-4808. doi: 10.1093/rheumatology/keac167. Rheumatology (Oxford). 2022. PMID: 35377447 Free PMC article. Clinical Trial.
Suitability of non-glucose-carbohydrates for parenteral nutrition.
Ahnefeld FW, Bässler KH, Bauer BL, Berg G, Bergmann H, Bessert I, Dick W, Dietze G, Dölp R, Dudziak R, Förster H, Geser CA, Grunst J, Halmagyi M, Heidland A, Heller L, Horatz K, Kuhlmann H, Kult J, Lutz H, Matzkies F, Mehnert H, Milewski P, Paulini K, Pesch J, Peter K, Rittmeyer P. Ahnefeld FW, et al. Among authors: matzkies f. Eur J Intensive Care Med. 1975 Nov;1(3):105-13. doi: 10.1007/BF00571657. Eur J Intensive Care Med. 1975. PMID: 812704 Review.
[Essential fatty acids].
Matzkies F. Matzkies F. Fortschr Med. 1980 Jun 26;98(24):940-4. Fortschr Med. 1980. PMID: 7429383 German.
Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA.
Meng A, Humeniuk R, Jürgensmeier JM, Hsueh CH, Matzkies F, Grant E, Truong H, Billin AN, Yu H, Feng J, Kwan E, Tarnowski T, Nelson CH. Meng A, et al. Among authors: matzkies f. Clin Pharmacol Ther. 2022 Feb;111(2):416-424. doi: 10.1002/cpt.2439. Epub 2021 Oct 27. Clin Pharmacol Ther. 2022. PMID: 34623640 Free PMC article.
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.
Werth VP, Fleischmann R, Robern M, Touma Z, Tiamiyu I, Gurtovaya O, Pechonkina A, Mozaffarian A, Downie B, Matzkies F, Wallace D. Werth VP, et al. Among authors: matzkies f. Rheumatology (Oxford). 2022 May 30;61(6):2413-2423. doi: 10.1093/rheumatology/keab685. Rheumatology (Oxford). 2022. PMID: 34498056 Free PMC article. Clinical Trial.
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
Winthrop KL, Tanaka Y, Takeuchi T, Kivitz A, Matzkies F, Genovese MC, Jiang D, Chen K, Bartok B, Jahreis A, Besuyen R, Burmester GR, Gottenberg JE. Winthrop KL, et al. Among authors: matzkies f. Ann Rheum Dis. 2022 Feb;81(2):184-192. doi: 10.1136/annrheumdis-2021-221051. Epub 2021 Nov 5. Ann Rheum Dis. 2022. PMID: 34740884 Free PMC article.
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
Tanaka Y, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Combe BG, Kivitz AJ, Bae SC, Keystone EC, Nash P, Matzkies F, Bartok B, Pechonkina A, Kondo A, Ye L, Guo Y, Tasset C, Sundy JS, Takeuchi T. Tanaka Y, et al. Among authors: matzkies f. Mod Rheumatol. 2022 Feb 28;32(2):263-272. doi: 10.1093/mr/roab030. Mod Rheumatol. 2022. PMID: 34910188 Clinical Trial.
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.
Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landewé RB, Atsumi T, Burmester GR. Westhovens R, et al. Among authors: matzkies f. Ann Rheum Dis. 2021 Jun;80(6):727-738. doi: 10.1136/annrheumdis-2020-219213. Epub 2021 Jan 15. Ann Rheum Dis. 2021. PMID: 33452004 Free PMC article. Clinical Trial.
168 results